ArticleCureus2025
Resolution of Erythema Nodosum Following FLT3-Targeted Therapy in Acute Myeloid Leukemia: A Case Report.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
A 59-year-old woman with persistent lower-leg erythema and pain, initially misdiagnosed as cellulitis, was later diagnosed with erythema nodosum (EN) and acute myeloid leukemia (AML), French-American-British (FAB) subtype M2, carrying a FLT3-internal tandem duplication (ITD) mutation. FLT3 mutations, common in AML-M2 and M4, activate PI3K/AKT and STAT5 pathways, driving cytokine production (tumor necrosis factor-alpha (TNF-α), IL-1β, IL-6, and granulocyte-macrophage colony-stimulating factor (GM-CSF)) and contributing to EN as a paraneoplastic phenomenon. This case highlights the role of FLT3 mutations in AML-associated inflammation and the importance of distinguishing paraneoplastic from drug-induced EN to guide treatment strategies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.